Clinical trial
A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
NCT00054834 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- March 31, 2003
- Completion date
- Not reported
- Enrollment
- 27
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
non-hodgkins lymphoma